GLG News by Renagel Prescribers for Chronic Renal Failure (US)
Analysis of:
New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these...
Analysis of:
Doctors See How Cancer Drug Can Damage Kidneys (www.washingtonpost.com)
This article brings more visibility to issue of effect of angiogenesis inhibitors on kidney function
Other mechanisms of injury have previously been described. Current case simply adds visibility and more definitive evidence of effect in humans
Mechanism described is likely not restricted...
Analysis of:
AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients (www.pipelinereview.com)
Ferumoxytol is not likely to gain market share and widespread use by hemodialysis centers. This new iron preparation offers no benefit over Ferrlecit and Venofer. Additionally, hemodialysis patient's are not inconvenienced by 30 minute infusion versus a 5-minute infusion.
Analysis of:
Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) (www.fda.gov)
DDAVP reduces urine output and is useful in the treatment of bedwetting (enuresis). However the reduction in excretion of water can be associated with water intoxication (hyponatremia). FDA advises that DDAVP is no longer considered indicated for the treatment of enuresis.
Analysis of:
Merck 'good' cholesterol drug meets trial goals (www.therapeuticsdaily.com)
Extended Release niacin has the second highest discontinuation rate. Laropiprant is a selective antagonist of the prostaglandin D(2) receptor subtype 1, which reduces niacin-induced vasodilation. Is it better than Aspirin?!
Analysis of:
Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows (www.pharmalive.com)
Prove the point that not all STATINS are the same. (Pleiotropic effects) Even though an observational study, still very impressive.
Analysis of:
J&J Ends Plan to Seek Wider Procrit Use (online.wsj.com)
The result of this study was not a surprise Inflammation and infection hamper the respose to EPO HIF 1 Alpha stabilizer is the answer for this group of patients
Analysis of:
Ranbaxy Gains Approval To Manufacture And Market Carvedilol Tablets In The U.S. Market (www.medicalnewstoday.com)
Carvidolol is an excellent drug indicated for the treatment of CHF Very Expensive drug on restricted formulary by many HMOs A good news to many physicians who were restricted in using this drug.
Analysis of:
Novartis's Tekturna shows promise in heart failure (www.reuters.com)
RAAS inhibition at many levels is an exciting idea! New Class of antihypertensive is welcomed by many physicians who struggle with BP controll in many of their HTN patients.
Analysis of:
Potential safety issue identified in ongoing phase 2 clinical study of HCV-796 (www.pipelinereview.com)
High prevalence of hepatitis C virus infection worldwide! Most therapies available have limited success esp. genotype 1 HCV genotype 1 most prevalent in US Most treatments are toxic Combination therapy need to devised
Page : 1 2 3 Next1 to 10 of 26
Most Popular Healthcare News
Expert Analyses | Source Article
www.boston.com
Medical devices not immune to recession worries
www.businessweek.com
Best Buy begins selling refurbished iPhones
www.medicalnewstoday.com
Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting
www.devicespace.com
Response Genetics, Inc. Signs Amendment to Its Master Service Agreement With GlaxoSmithKline (GSK) as Preferred Provider of Genetic Testing Services
online.wsj.com
Health-Care Outlays Climb at Slowest Rate in Years
January 7, 2009
The Best Buy in a Difficult Economy
January 6, 2009
I warned you. Genetic testing as well as the companies offering them ARE the way of the future!
January 5, 2009
What impact economic recession will have on the market for medical devices?
December 28, 2008
"Are my medical records protected, Doctor?"
December 28, 2008
The future is here